Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Blood-induced bone loss in murine hemophilic arthropathy is prevented by blocking the iRhom2/ADAM17/TNF-α pathway

Coline Haxaire, Narine Hakobyan, Tania Pannellini, Camila Carballo, David McIlwain, Tak W. Mak, Scott Rodeo, Suchitra Acharya, Daniel Li, Jackie Szymonifka, Xiangqian Song, Sébastien Monette, Alok Srivastava, Jane E. Salmon, Carl P. Blobel

Blood (2018) 132 (10): 1064–1074.

https://doi.org/10.1182/blood-2017-12-820571

Published: 2018

Includes: Supplemental data

Journal Articles

Prognostic Significance of DNA/Cig Flow Cytometry Assay in the ‘'era” of Novel Therapies in Multiple Myeloma (MM).

Xenofon Papanikolaou, MD, Jackie Szymonifka, Susann Szmania, Katie Stone, Sarah Waheed, MD, Saad Z Usmani, MD FACP, Christoph Heuck, MD, Frits van Rhee, MD, PhD, Joshua Epstein, DSc, Antje Hoering, Bart Barlogie, MD

Blood (2012) 120 (21): 2918.

https://doi.org/10.1182/blood.V120.21.2918.2918

Published: 2012

Journal Articles

Low Expression of Nuclear Glucocorticoid Receptor Gene NR3C1 in Newly Diagnosed Myeloma Correlates with Inferior Prognosis and Is Rescued by Thalidomide

Christoph Heuck, MD, Jackie Szymonifka, Qing Zhang, PhD, Saad Usmani, MD, FACP, Bijay Nair, MD, Sarah Waheed, MD, Yazan Alsayed, MD, Frits van Rhee, MD, PhD, Elias J. Anaissie, MD, Antje Hoering, PhD, John Crowley, PhD, John D Shaughnessy, Jr., PhD, Bart Barlogie, MD, PhD

Blood (2011) 118 (21): 988.

https://doi.org/10.1182/blood.V118.21.988.988

Published: 2011

Journal Articles

Phase II Study of Carfilzomib (CFZ) Combined with Other Anti-Myeloma Agents in Relapsed-Refractory Multiple Myeloma (RRMM) - Updates on the UARK Compassionate Use Protocol

Saad Usmani, MD, FACP, Jackie Szymonifka, Rachael Sexton, Susan Panozzo, Bijay Nair, MD, Sarah Waheed, MD, Yazan Alsayed, MD, John Crowley, PhD, Bart Barlogie, MD, Ph.D

Blood (2011) 118 (21): 2947.

https://doi.org/10.1182/blood.V118.21.2947.2947

Published: 2011

Journal Articles

Pomalidomide (Pom) in Relapsed and Refractory Multiple Myeloma (RRMM) - theUARK Compassionate Use Protocol,

Saad Usmani, MD, FACP, Sarah Waheed, MD, Jackie Szymonifka, Susan Panozzo, Nathan M Petty, Doug Steward, Bijay Nair, MD, Yazan Alsayed, MD, Antje Hoering, PhD, John Crowley, PhD, Bart Barlogie, MD, Ph.D

Blood (2011) 118 (21): 3995.

https://doi.org/10.1182/blood.V118.21.3995.3995

Published: 2011

Journal Articles

Super (S)-Beam for Advanced and Refractory Multiple Myeloma (ARMM)

Sarah Waheed, MD, Bijay Nair, MD, MPH, Yazan Alsayed, MD, Monica Grazziutti, Elias J. Anaissie, MD, Frits van Rhee, MD, PhD, Nathan Petty, Doug Steward, Jackie Szymonifka, Antje Hoering, PhD, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2010) 116 (21): 4800.

https://doi.org/10.1182/blood.V116.21.4800.4800

Published: 2010

Journal Articles

Pacmed Salvage Therapy for Advanced High-Risk Multiple Myeloma (AHRMM)

Yazan Alsayed, MD, Sarah Waheed, MD, Jackie Szymonifka, Bijay Nair, MD, MPH, Saad Usmani, MD, Frits van Rhee, MD, PhD, Elias J. Anaissie, MD, Monica Grazziutti, Antje Hoering, PhD, Bart Barlogie, MD, PhD

Blood (2010) 116 (21): 1969.

https://doi.org/10.1182/blood.V116.21.1969.1969

Published: 2010

Journal Articles

Total Therapy 2 (TT2) for Multiple Myeloma (MM): Contributions to Survival Outcomes of Dosing of Thalidomide (T), Dexamethasone (D) and Interferon (I) Maintenance Components.

Frits van Rhee, MD, PhD, Bart Barlogie, MD, PhD, Jackie Szymonifka, Elias J. Anaissie, MD, Bijay Nair, MD, MPH, Sarah Waheed, MD, Yazan Alsayed, MD, Nathan Petty, John Shaughnessy, Jr, PhD, Antje Hoering, PhD, John Crowley, PhD

Blood (2010) 116 (21): 1356.

https://doi.org/10.1182/blood.V116.21.1356.1356

Published: 2010

Journal Articles

Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy

Frits van Rhee, Jackie Szymonifka, Elias Anaissie, Bijay Nair, Sarah Waheed, Yazan Alsayed, Nathan Petty, John D. Shaughnessy, Jr, Antje Hoering, John Crowley, Bart Barlogie

Blood (2010) 116 (8): 1220–1227.

https://doi.org/10.1182/blood-2010-01-264333

Published: 2010

Journal Articles

Superior results of Total Therapy 3 (2003-33) in gene expression profiling–defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance

Bijay Nair, Frits van Rhee, John D. Shaughnessy, Jr, Elias Anaissie, Jackie Szymonifka, Antje Hoering, Yazan Alsayed, Sarah Waheed, John Crowley, Bart Barlogie

Blood (2010) 115 (21): 4168–4173.

https://doi.org/10.1182/blood-2009-11-255620

Published: 2010

Journal Articles

SUPER- BEAM (SB): Incorporation of Bortezomib, Thalidomide, Dexamethasone, Cisplatin and Rapamycin Into the BEAM Regimen for Multiple Myeloma (MM).

Sarah Waheed, MD, Yazan Alsayed, MD, PhD, Bijay Nair, MD, Jackie Szymonifka, John D Shaughnessy, Jr., Frits van Rhee, MD, PhD, Elias Anaissie, MD, PhD, Bart Barlogie, MD, PhD

Blood (2009) 114 (22): 3421.

https://doi.org/10.1182/blood.V114.22.3421.3421

Published: 2009

Journal Articles

Total Therapy 3 Successor (TT3-S) Protocol (2006-66)–Confirming Results Reported for Initial TT3 (TT3-I) Protocol (2003-33) for Newly Diagnosed Multiple Myeloma (MM).

Bijay Nair, MD, Yazan Alsayed, MD, PhD, Sarah Waheed, MD, Elias Anaissie, MD, PhD, Frits van Rhee, MD, PhD, Jackie Szymonifka, Antje Hoering, Ph.D., John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2009) 114 (22): 531.

https://doi.org/10.1182/blood.V114.22.531.531

Published: 2009

Journal Articles

Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study.

Blood (2009) 114 (22): 2878.

https://doi.org/10.1182/blood.V114.22.2878.2878

Published: 2009

Journal Articles

Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols

Antje Hoering, John Crowley, John D Shaughnessy, Jr, Klaus Hollmig, Yazan Alsayed, Jackie Szymonifka, Sarah Waheed, Bijay Nair, Frits van Rhee, Elias Anaissie, Bart Barlogie

Blood (2009) 114 (7): 1299–1305.

https://doi.org/10.1182/blood-2009-03-211953

Published: 2009

Journal Articles

Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival

Bijay Nair, John D. Shaughnessy, Jr, Yiming Zhou, Marie Astrid-Cartron, Pingping Qu, Frits van Rhee, Elias Anaissie, Yazan Alsayed, Sarah Waheed, Klaus Hollmig, Jackie Szymonifka, Nathan Petty, Antje Hoering, Bart Barlogie

Blood (2009) 113 (26): 6572–6575.

https://doi.org/10.1182/blood-2009-02-207803

Published: 2009

Journal Articles

Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group–directed intergroup trial S9003

Madhav V. Dhodapkar, Antje Hoering, Morie A. Gertz, Saul Rivkin, Jackie Szymonifka, John Crowley, Bart Barlogie

Blood (2009) 113 (4): 793–796.

https://doi.org/10.1182/blood-2008-07-172080

Published: 2009

Includes: Supplemental data

Journal Articles

Only Concomitant Presence of Cytogenetic Abnormalities in Randomly Sampled Bone Marrow and in MRI-Defined Focal Lesions Imparts Poor Prognosis and Is Associated with Gene Expression Profiling (GEP)-Based High-Risk Myeloma.

Bijay Nair, PhD, Yiming Zhou, PhD, Bart Barlogie, MD, PhD, Jeffrey Sawyer, PhD, Jackie Szymonifka, John Crowley, PhD, John D. Shaughnessy, Jr., PhD

Blood (2008) 112 (11): 1691.

https://doi.org/10.1182/blood.V112.11.1691.1691

Published: 2008

Journal Articles

Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease

Bart Barlogie, Frits van Rhee, John D. Shaughnessy, Jr, Joshua Epstein, Shmuel Yaccoby, Mauricio Pineda-Roman, Klaus Hollmig, Yazan Alsayed, Antje Hoering, Jackie Szymonifka, Elias Anaissie, Nathan Petty, Naveen S. Kumar, Geetika Srivastava, Bonnie Jenkins, John Crowley, Jerome B. Zeldis

Blood (2008) 112 (8): 3122–3125.

https://doi.org/10.1182/blood-2008-06-164228

Published: 2008

NARROW

Blood-induced bone loss in murine hemophilic arthropathy is prevented by blocking the iRhom2/ADAM17/TNF-α pathway

Prognostic Significance of DNA/Cig Flow Cytometry Assay in the ‘'era” of Novel Therapies in Multiple Myeloma (MM).

Low Expression of Nuclear Glucocorticoid Receptor Gene NR3C1 in Newly Diagnosed Myeloma Correlates with Inferior Prognosis and Is Rescued by Thalidomide

Phase II Study of Carfilzomib (CFZ) Combined with Other Anti-Myeloma Agents in Relapsed-Refractory Multiple Myeloma (RRMM) - Updates on the UARK Compassionate Use Protocol

Pomalidomide (Pom) in Relapsed and Refractory Multiple Myeloma (RRMM) - theUARK Compassionate Use Protocol,

Super (S)-Beam for Advanced and Refractory Multiple Myeloma (ARMM)

Pacmed Salvage Therapy for Advanced High-Risk Multiple Myeloma (AHRMM)

Total Therapy 2 (TT2) for Multiple Myeloma (MM): Contributions to Survival Outcomes of Dosing of Thalidomide (T), Dexamethasone (D) and Interferon (I) Maintenance Components.

Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy

Superior results of Total Therapy 3 (2003-33) in gene expression profiling–defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance

SUPER- BEAM (SB): Incorporation of Bortezomib, Thalidomide, Dexamethasone, Cisplatin and Rapamycin Into the BEAM Regimen for Multiple Myeloma (MM).

Total Therapy 3 Successor (TT3-S) Protocol (2006-66)–Confirming Results Reported for Initial TT3 (TT3-I) Protocol (2003-33) for Newly Diagnosed Multiple Myeloma (MM).

Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study.

Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols

Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival

Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group–directed intergroup trial S9003

Only Concomitant Presence of Cytogenetic Abnormalities in Randomly Sampled Bone Marrow and in MRI-Defined Focal Lesions Imparts Poor Prognosis and Is Associated with Gene Expression Profiling (GEP)-Based High-Risk Myeloma.

Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only